Liaise with pathologists to refine understanding of the prostate-specific antigen test

Kenneth A Sikaris, Bronwen A Ross and Teck Y Khong
Med J Aust 2013; 199 (10): . || doi: 10.5694/mja13.10883
Published online: 18 November 2013

To the Editor: Prostate-specific antigen (PSA) testing and prostate cancer, the focus of a number of recent articles in the Journal and a widely debated topic, are also the subject of an imminent position paper by the National Health and Medical Research Council (NHMRC). Given that there is general agreement on the potential for overdiagnosis and overtreatment of prostate cancer, it is important to continue our efforts to identify high-risk patients and patients for whom treatment is beneficial. The tools we have for this are the digital rectal examination, the PSA test and its refinements, and biopsy with Gleason scoring and its refinements.

  • Kenneth A Sikaris1,2
  • Bronwen A Ross3
  • Teck Y Khong3

  • 1 Melbourne Pathology, Melbourne, VIC.
  • 2 Department of Pathology, University of Melbourne, Melbourne, VIC.
  • 3 Royal College of Pathologists of Australasia, Sydney, NSW.


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.